Healthcare -
Biotechnology - NASDAQ - US
$ 0.0799
23.3 %
$ 16.4 M
Market Cap
-0.05
P/E
1. INTRINSIC VALUE
Balance Sheet
Cingulate Inc.
| Current Assets | 579 K |
| Cash & Short-Term Investments | 52.4 K |
| Receivables | 14.6 K |
| Other Current Assets | 512 K |
| Non-Current Assets | 3.09 M |
| Long-Term Investments | 0 |
| PP&E | 2.91 M |
| Other Non-Current Assets | 179 K |
| Current Liabilities | 10.2 M |
| Accounts Payable | 5.2 M |
| Short-Term Debt | 3 M |
| Other Current Liabilities | 2.03 M |
| Non-Current Liabilities | 135 K |
| Long-Term Debt | 135 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Cingulate Inc.
| Revenue | 0 |
| Cost Of Revenue | 583 K |
| Gross Profit | -583 K |
| Operating Expenses | 22.8 M |
| Operating Income | -22.8 M |
| Other Expenses | -22.7 M |
| Net Income | -23.5 K |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Cingulate Inc.
| Net Income | -23.5 K |
| Depreciation & Amortization | 583 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 813 K |
| Change in Working Capital | 7.1 M |
| Others | -26.1 M |
| Free Cash Flow | -15.3 K |
Wall Street Analysts Price Targets
Cingulate Inc.
CINGW has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
CINGW does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Cingulate Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 year ago
Sep 15, 2023
|
Bought
3.35 K USD
|
Callahan Jennifer L.
Corporate Controller
|
+ 5000
|
0.6697 USD |
|
1 year ago
Aug 11, 2023
|
Bought
1 M USD
|
Werth Peter J.
Director
|
+ 1823155
|
0.5485 USD |
|
1 year ago
May 15, 2023
|
Bought
2.02 K USD
|
Callahan Jennifer L.
Corporate Controller
|
+ 2000
|
1.01 USD |
|
1 year ago
May 12, 2023
|
Bought
4.32 K USD
|
Callahan Jennifer L.
Corporate Controller
|
+ 4000
|
1.08 USD |
|
1 year ago
May 12, 2023
|
Bought
6.18 K USD
|
Callahan Jennifer L.
Corporate Controller
|
+ 1030
|
6 USD |
|
2 years ago
Dec 16, 2022
|
Bought
52.4 USD
|
Schaffer Shane J.
Chief Executive Officer
|
+ 200
|
0.262 USD |
|
2 years ago
Dec 15, 2022
|
Bought
953 USD
|
Schaffer Shane J.
Chief Executive Officer
|
+ 3642
|
0.2617 USD |
|
2 years ago
Dec 16, 2022
|
Bought
10.2 K USD
|
Schaffer Shane J.
Chief Executive Officer
|
+ 10000
|
1.0166 USD |
|
2 years ago
Dec 13, 2022
|
Bought
28.4 K USD
|
Werth Peter J.
Director
|
+ 28934
|
0.9823 USD |
|
2 years ago
Dec 13, 2022
|
Bought
103 USD
|
Schaffer Shane J.
Chief Executive Officer
|
+ 396
|
0.2593 USD |
|
2 years ago
Dec 14, 2022
|
Bought
13.4 K USD
|
Schaffer Shane J.
Chief Executive Officer
|
+ 13267
|
1.01 USD |
|
2 years ago
Dec 13, 2022
|
Bought
1.75 K USD
|
Schaffer Shane J.
Chief Executive Officer
|
+ 1733
|
1.01 USD |
|
2 years ago
Dec 14, 2022
|
Bought
7.47 K USD
|
Callahan Jennifer L.
Corporate Controller
|
+ 7548
|
0.9894 USD |
|
2 years ago
Nov 23, 2022
|
Bought
1 K USD
|
Myers Laurie
EVP and COO
|
+ 1111
|
0.8998 USD |
|
2 years ago
Nov 29, 2022
|
Bought
1.5 K USD
|
Callahan Jennifer L.
Corporate Controller
|
+ 1530
|
0.98 USD |
|
2 years ago
Nov 28, 2022
|
Bought
3.42 K USD
|
Callahan Jennifer L.
Corporate Controller
|
+ 3487
|
0.9798 USD |
|
2 years ago
Nov 23, 2022
|
Bought
3 K USD
|
Gilgallon Craig S.
EVP, GC and Secretary
|
+ 3575
|
0.84 USD |
|
2 years ago
Nov 22, 2022
|
Bought
74.9 K USD
|
GIVENS GREGG WM
Director
|
+ 85000
|
0.8806 USD |
|
3 years ago
Dec 10, 2021
|
Bought
99 K USD
|
GIVENS GREGG WM
Director
|
+ 16500
|
6 USD |
|
3 years ago
Dec 10, 2021
|
Bought
49.8 K USD
|
Hargroves Thomas Jeffrey
Director
|
+ 8300
|
6 USD |
|
3 years ago
Dec 10, 2021
|
Bought
99 K USD
|
Schaffer Shane J.
Chief Executive Officer
|
+ 16500
|
6 USD |
|
3 years ago
Dec 10, 2021
|
Bought
49.8 K USD
|
Werth Peter J.
Director
|
+ 8300
|
6 USD |
7. News
8. Profile
Summary
Cingulate Inc. CINGW
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 16.4 M
Dividend Yield
0.00%
Description
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.
Contact
1901 West 47th Place, Kansas City, KS, 66205
https://www.cingulate.com
IPO
Date
None
Employees
13
Officers
Dr. Laurie A. Myers M.B.A., Ph.D.
Executive Vice President & Chief Operating Officer
Dr. Shane J. Schaffer Pharm.D.
Chief Executive Officer & Chairman of the Board
Dr. Raul R. Silva M.D.
Executive Vice President & Chief Science Officer
Ms. Jennifer L. Callahan CPA
Senior Vice President, Chief Financial Officer & Secretary
Thomas Dalton
Vice President of Investor & Public Relations
Dr. Matthew N. Brams M.D.
Executive Vice President & Chief Medical Officer